Navigation Links
$8 million NIH grant will fund multicenter clinical trial of stroke intervention drug
Date:4/22/2014

LOS ANGELES (April 22, 2014) Cedars-Sinai stroke intervention researchers have been informed that the National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health, will award an $8 million grant to fund a multicenter Phase II clinical trial of an experimental drug for stroke.

The drug, 3K3A-APC, will be used in combination with recombinant tissue plasminogen activator, or rtPA the "clot-busting" drug currently approved to treat ischemic strokes shortly after onset. In laboratory rodent studies, 3K3A-APC, used in combination with rtPA, had a protective effect on the lining of blood vessels, eliminating hemorrhaging, reducing brain damage, and improving animals' mobility after stroke. The new drug has completed a Phase I trial in 64 healthy volunteers to assess safety and dosing levels.

Ischemic strokes block arteries, depriving the brain of oxygen. The existing clot-buster, rtPA, may restore blood flow and often reverse the effects of a stroke if administered within three hours after symptoms begin. The drug, however, increases risk of internal bleeding in some patients, which can have brain-injuring and other harmful effects.

"Stroke is the fourth leading cause of death in the United States and a leading cause of disability, often leaving people to live out their lives with limited cognitive and physical skills. When patients receive rtPA within the three-hour time frame, the beneficial effects are often dramatic. But the drug is not without its limitations and potential side effects. Our objective in this and other studies is to spare more lives and livelihoods by making treatments more effective with fewer risks," said Patrick Lyden, MD, chair of Cedars-Sinai's Department of Neurology, director of the Stroke Program and the Carmen and Louis Warschaw Chair in Neurology.

The Phase II study will evaluate safety, tolerability and activity of 3K3A-APC when given after rtPA in patients who have experienced moderately severe ischemic stroke. The drug will be given intravenously as a 15-minute infusion every 12 hours for up to five treatments, and four dose levels will be evaluated. About 100 participants, ages 18 to 80, will be followed for 90 days.

APC activated protein C is a naturally occurring enzyme in the body that reduces inflammation, protects against cell death and acts as a blood thinner to prevent clotting. The drug 3K3A-APC is a synthesized and slightly modified protein that maintains APC's cell-protective and anti-inflammatory benefits while reducing anticlotting activity. It is designed, therefore, to protect brain cells and cerebral blood vessels while reducing the risk of treatment-related bleeding.

The clinical trial grant was awarded to Lyden, the study's principal investigator. He was also principal investigator of the Phase I trial and a major contributor to the clinical trial leading to Food and Drug Administration approval in 1996 of rtPA, still the only proven and approved drug for stroke treatment.

The award is also in conjunction with a NeuroNEXT Infrastructure Resource Access award to ZZ Biotech LLC, the company developing 3K3A-APC. Kent Pryor, PhD, the company's chief operating officer, will be the principal investigator for this aspect of the study. ZZ Biotech will also enlist the collaboration of NeuroNEXT, a research network funded by the National Institute of Neurological Disorders and Stroke.

The institute created NeuroNEXT the Network for Excellence in Neuroscience Clinical Trials to increase its ability to explore promising treatments by partnering with academia, private foundations and industry. With this support, the researchers will have access to the NeuroNEXT Clinical Coordinating Center at Massachusetts General Hospital and Data Coordinating Center at the University of Iowa. The University of Rochester in New York will provide a central laboratory, and about 15 NeuroNEXT centers will participate in the study.

The new drug originated in the laboratory of John Griffin, PhD, professor in the Department of Molecular and Experimental Medicine at The Scripps Research Institute, which licensed development rights to ZZ Biotech.

Berislav Zlokovic, director of the Zilkha Neurogenetic Institute and professor and chair of the Department of Physiology and Biophysics at Keck School of Medicine of the University of Southern California, and scientific founder of ZZ Biotech, will be a co-investigator of the Phase II trial.

ZZ Biotech is a company developing APC and related products for stroke and other neurological disorders. Zlokovic is the scientific founder, Pryor is the chief operating officer, Griffin is a member of the scientific advisory board and Lyden is a consultant.


'/>"/>

Contact: Sandy Van
sandy@prpacific.com
808-526-1708
Cedars-Sinai Medical Center
Source:Eurekalert

Related medicine news :

1. NIH awards $20 million over 5 years to train next generation of global health researchers
2. Scientist awarded $1 million grant to develop tools for hepatitis C treatment discovery
3. David H. Koch donates $10 million to Mount Sinais Jaffe Food Allergy Institute
4. $9 million grant awarded to UH to study, treat learning disabilities
5. New report shows 15 million babies born too soon every year
6. Southeast program to fight diabetes awarded nearly $10 million by HHS
7. OHSU study: Misdiagnosis of MS is costing health system millions per year
8. Enzyme corrects more than 1 million faults in DNA replication
9. 53 million Americans might have diabetes by 2025, according to a new study in Population Health Management
10. Asthma Cases Continue to Rise in U.S., Affecting Millions
11. UC San Diego Superfund Research Program receives $15 million grant renewal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... health professionals, announced today its affiliation with Tennessee Counseling Association. This ... the network of the Tennessee Counseling Association, adding exclusive benefits and promotional offers. ...
(Date:6/26/2016)... Battle Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... abuse, joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table ... held in honor of the city’s history as home to some of the world’s ...
(Date:6/25/2016)... ... 25, 2016 , ... Experts from the American Institutes for ... Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR ... care planning, healthcare costs and patient and family engagement. , AIR researchers will ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic ... many turn to unhealthy avenues, such as drug or alcohol abuse, as a coping ... released tools for healthy coping following a traumatic event. , Trauma sufferers tend to ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Pa. , June 23, 2016 Bracket ... will launch its next generation clinical outcomes platform, Bracket eCOA ... Meeting held on June 26 – 30, 2016 in ... the first electronic Clinical Outcome Assessment product of its kind ... Booth #715. Bracket eCOA 6.0 is a flexible ...
(Date:6/23/2016)... and INDIANAPOLIS , June 23, 2016 ... Lilly Diabetes Tomorrow,s Leaders Scholarship is any indication, the ... announced today online at www.diabetesscholars.org by the ... diabetes stand in the way of academic and community ... Foundation,s scholarship program since 2012, and continues to advocate ...
(Date:6/23/2016)... Revolutionary technology includes multi-speaker listening to conquer ... in advanced audiology and hearing aid technology, has today ... world,s first internet connected hearing aid that opens up ...      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ) , ... , TwinLink™ - the first dual communication ...
Breaking Medicine Technology: